Psychedelic Medicine

The state of Oregon will officially vote on legalizing psilocybin psychotherapy in the upcoming November election. The initiative focuses solely on licensed and regulated psychedelic-assisted psychotherapy in clinical environments.

New research is offering the first clinical trial insights into microdosing THC to treat chronic pain. The results of the small trial suggest tiny doses of THC may confer clinically apparent reductions in pain without inducing psychoactive effects.

A new pilot study has demonstrated nitrous oxide, commonly known as laughing gas, may help military veterans suffering from PTSD. A larger trial is now underway after several studies demonstrated potential new uses for the gas.

A study has found smoking high-THC marijuana or concentrates does not result in greater levels of intoxication. The research adds weight to a body of evidence suggesting proposed roadside THC tests may not correlate with driving impairment.

A new Johns Hopkins study, looking at how psilocybin influences a mysterious brain region called the claustrum, is just one of several compelling recent articles shining a light on how our brains generate our experience of consciousness.

A new study is looking at the long-term efficacy of MDMA-assisted psychotherapy for the treatment of PTSD, finding the substantial beneficial effects of the therapy hold strong for over a year and patients continue to improve after the MDMA sessions.

How does psilocybin create a feeling of ego dissolution, and what chemicals in the brain create our subjective sense of self? New Atlas spoke to the lead author on a compelling new study delving into these questions, Natasha Mason, to learn more.

Scientists have discovered a new mechanism to help illustrate the rapid antidepressant qualities of ketamine. Imaging patients with depression revealed ketamine’s effects are a result of its interaction with a particular kind of serotonin receptor.

A new study investigates the strange phenomenon of DMT-induced encounters with bizarre entities. The massive survey finds not only do most people who consume this psychedelic encounter unusual beings, but many atheists leave the experience with new beliefs.

Psychedelic pharma company MindMed has announced the development of a compound designed to stop the effects of an LSD experience. The compound is designed to help clinicians make psychedelic therapy sessions safer if patients become uncomfortable.

With psilocybin on the cusp of becoming a clinically validated and approved medicine, scientists are exploring new ways to produce the chemical. Now a team has presented a novel method of producing the psychedelic chemical using common yeast.

A new study has gone to extraordinary lengths to investigate how strong the placebo effect may be in psychedelic research. The experiment staged a fake party to explore exactly how much of a psychedelic experience can be generated with a placebo.